Researchers of this study established clinical validity for the Lupus Impact Tracker and noted the tool was clinically acceptable for patients with systemic lupus erythematosus and physicians to administer, according to recent research.
“The results of this study, in addition to the initial validation analysis, confirm that the [Lupus Impact Tracker] LIT is a reliable, valid, and responsive instrument,” Meenakshi Jolly, MD, from Rush University Medical Center in Chicago, and colleagues wrote in their study. “Factor analysis confirmed that one factor is sufficient to represent the 10 LIT items, which supports the scoring of LIT in a single scale.”
To validate the LIT, Jolly and colleagues asked 325 patients to complete the LIT, Medical Outcomes Study Short Form 36 (version 2), Patient Health Questionnaire 9 (PHQ-9), LupusQoL and patient LIT feedback questionnaire, while rheumatologists completed the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index and physician LIT feedback questionnaire, according to the abstract. The mean patient age was 42 years. Of the patients enrolled, 90% were female. Overall, 53% were white and 33% were African-American.
The researchers found baseline SELENA-SLEDAI scores were 4.28 ± 3.8 points and the physician’s global assessment was 1.04 ± 0.8 points. At 3 months, the scores had increased to 4.09 ± 3.79 points and 0.94 ± 0.73 points, respectively, with high internal consistency reliability at both baseline and follow-up visits, according to the abstract.
Jolly and colleagues also found the LIT score was validated against other patient-reported outcome measures. Construct validity was established and was specifically highly responsive to changes in patient health status. The researchers noted LIT was acceptable and feasible in a clinical setting for both patients and physicians, according to results from the feedback questionnaire. – by Jeff Craven
Disclosures: Jolly repots consulting fees from GlaxoSmithKline, a grant from Pfizer and holds intellectual property rights on the Lupus patient-reported outcome tool and Lupus Impact Tracker. Garris and Oglesby own stock in GlaxoSmithKline.